New COVID vaccine trial aims to outsmart evolving variants

NCT ID NCT07089706

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 36 times

Summary

This study tests an updated mRNA COVID-19 vaccine designed to target current virus variants. About 832 adults, especially those 65+ or with risk factors, will receive the vaccine to check how well it boosts immunity and to monitor for side effects. The goal is to ensure the vaccine remains effective as the virus changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

DelRicht Research-Atlanta
RECRUITING

Atlanta, Georgia, 30329, United States
DelRicht Research-Baton Rouge
RECRUITING

Baton Rouge, Louisiana, 70769, United States
DelRicht Research-Gulfport
RECRUITING

Gulfport, Mississippi, 39503, United States
DelRicht Research-New Orleans
RECRUITING

New Orleans, Louisiana, 70115, United States
DelRicht Research-Tulsa
RECRUITING

Tulsa, Oklahoma, 74133, United States

Conditions

Explore the condition pages connected to this study.

COVID-19